Statins: Lowering Cholesterol and Stabilizing Plaque
Statins are among the most prescribed — and most argued-about — drugs on earth, taken by hundreds of millions to prevent heart attacks and strokes. But here's the surprise: their biggest benefit may not come from the cholesterol number they lower at all. Understanding how they really work explains why they're started even in people whose cholesterol looks fine after a heart attack — and why grapefruit juice can turn them dangerous.
A man survives a heart attack, and before he leaves hospital he's started on a high-dose statin — even though his cholesterol reading wasn't especially high. He's puzzled: why a cholesterol drug if his cholesterol was 'normal'? The answer reframes what statins really do. They lower cholesterol, yes — but they also calm and stabilize the fatty plaques lining his arteries, making them far less likely to rupture and trigger the next clot. That plaque-stabilizing power, as much as the number, is why nearly every heart-attack survivor goes home on one.
How statins work
Statins block the liver's cholesterol factory. The liver makes cholesterol using a rate-limiting enzyme called HMG-CoA reductase. Statins (atorvastatin, rosuvastatin, simvastatin) block this enzyme, so the liver makes less cholesterol — and, running short, it responds by building more LDL receptors on its surface to pull LDL ('bad' cholesterol) out of the blood. The net effect is a big drop in blood LDL. But statins also do more than lower the number: they stabilize atherosclerotic plaques and calm the inflammation in artery walls (their so-called 'pleiotropic' effects), which is why they reduce heart attacks and strokes even beyond what the LDL drop alone would predict. Their proven uses span both prevention in high-risk people and treatment after any cardiovascular event.
The side effects
Statins are generally well tolerated, but the side effect everyone worries about is muscle-related: aching muscles (myalgia) are common, and rarely the muscle can break down severely (rhabdomyolysis), releasing the enzyme CK and injuring the kidneys. They can also cause a mild, usually harmless rise in liver enzymes, and slightly increase the risk of developing diabetes. Two interaction points matter: grapefruit juice inhibits the gut enzyme (CYP3A4) that clears some statins — raising their levels and the risk of muscle toxicity (the exact case from the metabolism articles) — and combining a statin with a fibrate (especially gemfibrozil) also raises the myopathy risk. Statins are avoided in pregnancy and active liver disease.
It's not just the number — it's the plaque. Statins reduce cardiovascular events more than you'd expect from the LDL fall alone, because they stabilize the vulnerable, inflamed plaques that rupture to cause heart attacks. That's why they're given after a heart attack or stroke almost regardless of the starting cholesterol, and why the modern approach is often 'treat the risk, not just the number.' A high-risk patient benefits from a statin even with a seemingly acceptable LDL.
- Statins block HMG-CoA reductase → liver makes more LDL receptors → LDL falls.
- They also stabilize plaques & reduce inflammation ('pleiotropic') — benefit beyond the number.
- Main side effect is muscle: myalgia, rarely rhabdomyolysis (↑CK, kidney injury).
- Grapefruit (CYP3A4) and fibrates raise statin muscle toxicity; avoid in pregnancy/liver disease.
- Withholding a statin after a heart attack because cholesterol looks 'normal'. It stabilizes plaque.
- Ignoring muscle symptoms; severe myopathy/rhabdomyolysis needs the statin stopped and CK checked.
- Overlooking the grapefruit and fibrate interactions that raise statin levels/muscle risk.
- Using a statin in pregnancy. It's contraindicated.
Statins lower LDL mainly by:
- Statins block HMG-CoA reductase; the liver then clears more LDL from the blood.
- They also stabilize plaque & reduce inflammation — benefit beyond the LDL number.
- Main risk is muscle (myalgia, rare rhabdomyolysis); grapefruit & fibrates raise it.
- Given after heart attacks regardless of baseline cholesterol; avoided in pregnancy.
- Katzung BG. Basic & Clinical Pharmacology — Agents Used in Dyslipidemia (statins).
- Brunton LL, et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics — Drug therapy for hypercholesterolemia.
- Rang HP, Dale MM, et al. Rang & Dale's Pharmacology — Lipoprotein metabolism & statins.
- ACC/AHA & ESC/EAS Cholesterol Guidelines — Statin therapy & cardiovascular risk.
- Whalen K. Lippincott Illustrated Reviews: Pharmacology — HMG-CoA reductase inhibitors.
